Application | Comment | Organism |
---|---|---|
medicine | LHN/A vaccine protects mice against challenge with BoNT/A subtypes A1, A2, and A3 | Clostridium botulinum |
medicine | LHN/A vaccine protects mice against challenge with BoNT/A subtypes A1, A2, and A3,the LHN/B vaccine is also highly efficacious | Clostridium botulinum |
medicine | LHN/B vaccine protects mice against challenge with BoNT/A subtypes A1, A2, and A3 | Clostridium botulinum |
Cloned (Comment) | Organism |
---|---|
catalytically inactive, mutated fragments, designated LHN, comprise the light chain and translocation domains of each neurotoxin and are devoid of any neuron-binding activity. Using codon-optimized genes, LHN fragments, derived from BoNT serotype A, are expressed in Escherichia coli in high yield as soluble proteins | Clostridium botulinum |
catalytically inactive, mutated fragments, designated LHN, comprise the light chain and translocation domains of each neurotoxin and are devoid of any neuron-binding activity. Using codon-optimized genes, LHN fragments, derived from BoNT serotype B, are expressed in Escherichia coli in high yield as soluble proteins | Clostridium botulinum |
catalytically inactive, mutated fragments, designated LHN, comprise the light chain and translocation domains of each neurotoxin and are devoid of any neuron-binding activity. Using codon-optimized genes, LHN fragments, derived from BoNT serotypes A and B, are expressed in Escherichia coli in high yield as soluble proteins | Clostridium botulinum |
Protein Variants | Comment | Organism |
---|---|---|
E224Q/H227Y | the mutation removes the endopeptidase activity of BoNT/A LH fragment | Clostridium botulinum |
E231Q/H234Y | the mutation removes the endopeptidase activity of BoNT/B LH fragment | Clostridium botulinum |
Organism | UniProt | Comment | Textmining |
---|---|---|---|
Clostridium botulinum | P10844 | BoNT/B | - |
Clostridium botulinum | P10844 | BoNT/B; BoNT/A1, BoNT/A3, BoNT/B1, and BoNT/B4 from strains ATCC 3502, NCTC 2012, Okra, and Eklund 17B strains, respectively | - |
Clostridium botulinum | P10845 | BoNT/A | - |
Purification (Comment) | Organism |
---|---|
native BoNT/A1 and BoNT/A3, by ultrafiltration, hydrophobic interaction and anion exchange chromatography, followed by hydroxyapatite chromatography and dialysis | Clostridium botulinum |
native BoNT/A1, BoNT/A3, BoNT/B1, and BoNT/B4 from strains ATCC 3502, NCTC 2012, Okra, and Eklund 17B strains, respectively, by ultrafiltration, hydrophobic interaction and anion exchange chromatography, followed by hydroxyapatite chromatography and dialysis | Clostridium botulinum |
native BoNT/B1, and BoNT/B4 by ultrafiltration, hydrophobic interaction and anion exchange chromatography, followed by hydroxyapatite chromatography and dialysis | Clostridium botulinum |
Subunits | Comment | Organism |
---|---|---|
More | enzyme model with light chain LC or effector domain, showing the catalytic activity, heavy chain HC binding domain binding to neuronal receptors, after which the HN translocation domain mediates the entry of the light chain into the nerve cell | Clostridium botulinum |
Synonyms | Comment | Organism |
---|---|---|
BoNT/A | - |
Clostridium botulinum |
BoNT/B | - |
Clostridium botulinum |
botulinum neurotoxin type A | - |
Clostridium botulinum |
botulinum neurotoxin type B | - |
Clostridium botulinum |
Temperature Optimum [°C] | Temperature Optimum Maximum [°C] | Comment | Organism |
---|---|---|---|
37 | - |
assay at | Clostridium botulinum |
pH Optimum Minimum | pH Optimum Maximum | Comment | Organism |
---|---|---|---|
7.4 | - |
assay at | Clostridium botulinum |